Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation

Prenatal Diagnosis

Volumn 34, Issue 7, 2014, Pages 649-654

  Ghidini, Alessandro ^a  

^a INOVA ALEXANDRIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

DRUG EFFICACY; DRUG SAFETY; FETUS WASTAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; OSTEOPENIA; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME; REVIEW; THROMBOPHILIA; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; OBSTETRIC LABOR COMPLICATIONS; PLACENTA DISEASES; PREGNANCY; REPRODUCTION;

CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OBSTETRIC LABOR COMPLICATIONS; PLACENTA DISEASES; PLACENTATION; PREGNANCY; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84928590987     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4385     Document Type: Review

References (76)

1. American College of Obstetricians and Gynecologists: Antiphospholipid syndrome. Practice Bulletin # 132. Obstet Gynecol 2012;120:1514-21
2. Duhl AJ, Paidas MJ, Ural SH, et al. (Pregnancy and Thrombosis Working Group). Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;197; 457-e1-21
3. Wu P, Poole TC, Pickett JA, et al. Current obstetric guidelines on thromboprophylaxis in the United Kingdom: evidence based medicine? Eur J Obstet Gynecol Reprod Biol 2013;168(1):7-11.
4. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002;101(1):6-14.
5. Lykke JA, Bare LA, Olsen J, et al. Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost 2012;10:1320-5
6. Facchinetti F, Marozio L, Frusca T, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009;200:46.e1-5.
7. Kalk JJ, Huisjes AJ, de Groot CJ, et al. Recurrence rate of preeclampsia in women with thrombophilia: influenced by low molecular weight heparin treatment? Neth J Med 2004;62:83-7
8. Dizon-Townson D, Miller C, Sibai B, et al. for the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106:517-24
9. Kahn SR, Platt R, McNamara H, et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol 2009; 200:151. e1-9
10. Silver RM, Zhao Y, Spong CY, et al. for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Units (MFMU) Network. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010; 115:14-20
11. Rodger MA, Walker MC, Smith GN, et al. Is Thrombophilia Associated with Placenta-Mediated Pregnancy Complications? A Prospective Cohort Study. J Thromb Haemost 2014. doi: 10.1111/jth.12509.
12. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171-96
13. Riyazi N, Leeda M, de Vries JI, et al. Low- molecular- weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998;80:49-54
14. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000;83:693-7
15. Ogueh O, Chen MF, Spurll G, et al. Outcome of pregnancy in women with hereditary thrombophilia. Int J Gynaecol Obstet 2001;74:247-53
16. Kupferminc M, Fait G, Many A, et al. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy 2001;20:35-44.
17. Grandone E, Brancaccio V, Colazzo D, et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 2002;78:371-5
18. Carp H, Dolitsky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003;1:433-8
19. Paidas M, Ku DH, Triche E, et al. Does heparin therapy improve pregnancy outcome in patients with thrombophilias? J Thromb Haemost 2004;2:1194-5
20. Grandone E, De Stefano V, Rossi E, et al. Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants. Blood Coagul Firbinolysis 2008;19:226-30
21. Kupferminc MJ, Rimon E, Many A, et al. Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. J Matern Fetal Neonatal Med. 2011;24(8):1042-5.
22. Gris JC, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103(10):3695-9
23. De Vries JP, Van Pampus MG, Hague WM, Bezemer PD, Joosten JH. Low-molecular weight heparin added to aspirin in the prevention of recurrent early-onset preeclampsia with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012;10:64-72
24. Tormene D, Grandone E, De Stefano V, et al. Obstetric complications and pregnancy-related venous thromboembolism: the effect of low molecular weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation. Thromb Haemost 2012;107:477-84
25. American College of Obstetricians and Gynecologists. Inherited thrombophilias in pregnancy. Practice Bulletin # 138. Obstet Gynecol 2013;122:706-16
26. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Chest 2012;141:e691S-736
27. Ferrazzani S, D'Alessio MC, Fatigante G, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 2006;25:115-27
28. Folkeringa N, Brouwer JL, Korteweg FJ, et al. High risk of pregnancy-related venous thrombosis in women with multiple thrombophilic defects. Br J Haematol 2007;136:656-61
29. Urban G, Vergani P, Tironi R, et al. Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy. Int J Fertil Womens Med 2007;52:59-67
30. Kupferminc M, Rimon E, Many A, et al. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis. 2011;22(2):123-6.
31. Conserva V, Muggiasca M, Arrigoni L, et al. Recurrence and severity of abnormal pregnancy outcome in patients treated by low-molecular-weight heparin: a prospective pilot study. J Matern Fetal Med 2012;25:1467-73
32. Kamda JD, Ghidini A, Landy H, et al. Antithrombotic therapy and placental implantation-related adverse pregnancy outcomes. Reprod Sci 2012;19(3S):378A
33. Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2010;16:CD006780
34. Rodger MA, Carrier M, Le Gal G, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014;123:822-8.
35. Dolitzky M, Inbal A, Segal Y, et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006;86(2):362-6.
36. Fawzy M, Shokeir T, El-Tatongy M, et al. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008;278:33-8
37. Badawy AM, Khiary M, Sherif LS, et al. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown etiology. J Obstet Gynaecol 2008;28:280-4
38. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 1586-96.
39. Giancotti A, La Torre R, Spagnuolo A, et al. Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. J Matern Fetal Neonatal Med 2012;25:1191-4.
40. Laskin CA, Spitzer KA, El-Tatongy M, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009;36:279-87.
41. Rodger MA, Silver RM. Coagulation disorders in pregnancy. In Creasy and Resnik's Maternal-Fetal Medicine, Creasy RK, Resnik MD, Iams JD, Lockwood CJ, Moore TR, Greene MF (eds). Elsevier-Saunders: Philadelphia, PA, 2014;878-905.
42. Mello G, Paretti E, Fatini C, et al. Low-molecular weight heparin lowers the recurrence risk of preeclampsia and restores the physiologic vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45:86-91
43. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009;7:58-64
44. Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for secondary prevention of placental vascular complications in women with abruption placentae. The pilot randomized controlled NOH-AP trial. Thromb Haemost 2010;104:771-9
45. Gris JC, Chauleur C, Molinari N, et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 2011;106:1053-61
46. Martinelli I, Ruggenenti P, Cetin I, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012;119:3269-75.
47. Redline RW. Thrombophilia and placental pathology. Clin Obstet Gynecol 2006;49(4):885-94.
48. Franco C, Walker M, Robertson J, et al. Placental infarction and thrombophilia. Obstet Gynecol 2011;117:929-34.
49. Abou-Nasser K, Kovacs MJ, Kahn SR, et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. Thromb Haemost 2007;98:163-71
50. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003;9:331-7
51. Hossain N, Schatz F, Paidas MJ. Heparin and maternal-fetal interface: why should it work to prevent pregnancy complications? Thromb Res 2009;124:653-5
52. Kingdom JCP, Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies? Blood 2011;118:4780-8
53. Carr DB, McDonald GB, Brateng D, et al. The relationship between hemodynamics and inflammatory activation in women at risk for preeclampsia. Obstet Gynecol 2001;98:1109-16
54. Lever R, Hoult RS, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000;129:533-40
55. Manduteanu I, Voinea M, Capraru M, et al. A novel attribute of enoxaparin: inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology 2002;65:32-7
56. Wan MX, Zhang XW, Törkvist L, Thorlacius H. Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling. Inflamm Res. 2001;50(12):581-4.
57. Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L- and P-Selectin and inhibit acute inflammation. Blood 1993;82:3253-8
58. Oberkersch R, Attoresi AI, Calabrese GC. Low-molecular weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res 2010;125:240-5
59. Di Simone N, Di Nicuolo F, Sanguinetti M, et al. Low molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors. Placenta 2007;28:298-304
60. Bose P, Black S, Kadyrov M, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005;192:23-30.
61. Quenby S, Mountfield S, Cartwright JE, et al. Effects of low-molecular-weight and unfractionated heparin on trophoblast function. Obstet Gynecol 2004;104:354-61.
62. Ganapathy R, Whitley GS, Cartwright JE, et al. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 2007;22:2523-7.
63. Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to heparin. Obstet Gynecol 2011;117:1375-83
64. Lash GE, Warren A, Underwood S, Baker PN. Vascular endothelial growth factor is a chemoattractant for trophoblast cells. Placenta 2003;24:549-56
65. Rosenberg VA, Buhimschi IA, Lockwood CJ, et al. Heparin levates circulating soluble fms-like tyrosine kinase-1 immunoreactivity I pregnant women receiving anticoagulation therapy. Circulation 2011;124:2543-53
66. Yinon Y, Kingdom JC, Odutayo A, et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010;122:1846-53
67. Reantragoon S, Arrigo LM, Seoud MM, et al. Specific heparin fractions suppress endothelin-1 production in cultured human umbilical vein endothelial cells. Arch Biochem Biophys. 1994;314(2):315-22.
68. Torricelli M, Reis FM, Florio P, et al. Low-molecular-weight heparin improves the performance of uterine artery Doppler velocimetry to predict preeclampsia and small-for-gestational age infant in women with gestational hypertension. Ultrasound Med Biol 2006;32(9):1431-5.
69. Drewlo S, Walker M, McLeod A, Dodd J, Kigdom J. Heparin in human placental development and the prevention of placental complications of pregnancy. Fetal Matern Med Rev 2010;21:185-203
70. Jeyabalan A, Conrad KP. Renal function during normal pregnancy and preeclampsia. Front Biosci 2007;12:2425-37.
71. Sarig G, Vidergor G, Brenner B. Assessment and management of high-risk pregnancies in women with thrombophilia. Blood Rev 2009;23:143-7.
72. Rodger MA, Kahn SR, Cranney A, et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 2007;5:1600-6
73. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. A meta-analysis. Obstet Gynecol 2010;116:43-50
74. Bujold E, Morency AM, Roberge S, et al. Acetylsalicylic acid for the prevention of preeclampsia and intra-uterine growth restriction. J Obstet Gynaecol Can 2009;31:818-26
75. Brenner B, Hoffman R, Carp H, et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 3:227-9
76. Kingdom JC, Walker M, Proctor LK, et al. Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial. J Thromb Haemost 2011;9:1483-92